Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Investigational

9,777

Other

107,652

Possibly Marketed Outside US

10,255

US Approved Rx

1,612

US Previously Marketed

1,444

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Vascular endothelial growth factor receptor 2

31

DNA

28

Dopamine D2 receptor

26

Peroxisome proliferator-activated receptor gamma

26

Serotonin 1a (5-HT1a) receptor

26

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Phase II

516

Phase III

226

Phase I

216

Not Provided

83

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

9,777

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Unknown

129

Cancer

91

Breast cancer

89

Non-small cell lung cancer

76

Solid tumors

76

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

1,084

Palliative

58

Curative

57

Preventing

51

Diagnostic

25

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

435

CNS Penetrant

204

CNS Non-penetrant

39

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Pfizer

94

GlaxoSmithKline

62

Eli Lilly

48

AstraZeneca

46

Novartis

44

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

7,070

Protein

1,618

Structurally Diverse

499

Nucleic Acid

194

Concept

193

All Match

Any Match

Exclude Selected

Exclude Selected

INN Stem

Monoclonal antibodies(-mab)

192

Chemical substance(-ine)

74

Tyrosine-kinase inhibitors(-tinib)

70

Peptides and glycopeptides(-tide)

67

Gene Therapy vectors(-vec)

63

All Match

Any Match

Exclude Selected

Exclude Selected

GInAS Tag

KEW

41

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

9,777

CAS

8,997

NCI_THESAURUS

7,392

PUBCHEM

7,090

INN

6,598

All Match

Any Match

Exclude Selected

Exclude Selected

Protein Type

MONOCLONAL ANTIBODY

724

PEPTIDE

108

MONOCLONAL ANTIBODY CONJUGATE

99

BISPECIFIC ANTIBODY

82

FUSION PROTEIN

41

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

9,777

Salts, Hydrates, Esters, etc.

3,046

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 10 of 9,777 results

First page disabled
Previous page disabled
1
Next page
Next page

rel-(3R,5S,6E)-7-[2-(4-Fluoro-3-methylphenyl)-4,4,6,6-tetramethyl-1-cyclohexen-1-yl]-3,5-dihydroxy-6-heptenoic acid

XW8UFD4YLA

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (RACEMIC)

Dalvastatin is a synthetic HMG-CoA reductase inhibitor developed by Rhône-Poulenc Rorer. Dalvastatin is a prodrug and is itself an inactive lactone. After oral ingestion, the drug is hydrolyzed in vivo to the corresponding beta-hydroxy acid, which is...

the pharmacologically active form. HMG-CoA reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway. An active form of dalvastatin inhibits HMG-CoA reductase with IC50 of 3.4 nM. In ex vivo assay, orally administered dalvastatin inhibited cholesterol biosynthesis in rat liver slices with an ED50 value of 0.9. The efficacy of dalvastatin to lower cholesterol was investigated in the clinical trials in the 1990s, but no results were reported.

Dordaviprone

9U35A31JAI

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

TRAIL-activated apoptotic signaling pathway

response to stress

D2-like dopamine receptor

Conditions:

Non-Hodgkin's lymphoma

Multiple myeloma

TIC10 (NSC350625 or ONC201) is a small-molecule compound belongs to a chemical class known as imipridones, that possess a unique three-ring heterocycle with two substitutable basic amines. ONC201 has anti-proliferative and pro-apoptotic effects again...

st a broad range of tumor cells but not normal cells. The mechanism of action of ONC201 involves engagement of PERK-independent activation of the integrated stress response, leading to tumor upregulation of DR5 and dual Akt/ERK inactivation, and consequent Foxo3a activation leading to upregulation of the death ligand TRAIL. The isomeric structure of TIC10/ONC201 is critical to its activity: anti-cancer activity is associated with the angular structure and not the linear isomer. Clinical trials are evaluating the single agent efficacy of ONC201 in multiple solid tumors and hematological malignancies and exploring alternative dosing regimens. Oncoceutics is developing ONC 201 as a potential therapy for treatment of p53-deficient cancers (including solid tumours).

CABIOTRAXETAN LUTETIUM LU-177

5U8L0A8I80

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

ETHYL XIMENYNATE

MEQ6O2FROG

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Friluglanstat

L65P4UM6KV

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

OLEOCANTHAL

AC7QO6038O

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Labuxtinib

QNX4G754W6

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Lerzeparib

FA3YB8W7X9

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Uplarafenib

TQU3V7CXC3

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ACHIRAL)

Irpagratinib

X46B7JM4A8

Export Data
Search for Structure

Status:

Investigational

Class (Stereo):

CHEMICAL (ABSOLUTE)

Showing 1 - 10 of 9,777 results

First page disabled
Previous page disabled
1
Next page
Next page

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1